« Back to news

Ventus Therapeutics Opens New Facility in Waltham, MA as First Phase of Global Expansion

New 13,000-square-foot facility will allow Ventus to strategically expand its workforce and R&D capacity and further advance its therapeutic pipeline and ReSOLVE platform

Waltham, Mass. & Montreal, QC — September 6, 2022 — Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the opening of a new office and lab facility in Waltham, Massachusetts as the first phase of its planned global expansion.

“The new Waltham facility triples our U.S. laboratory space and allows Ventus to strategically expand its workforce and R&D capacity, significantly increasing the number of targets we will be able to evaluate using ReSOLVE each year,” said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. “With this expansion, we are well positioned to continue to build our in-house capabilities to further advance ReSOLVE with leading talent in the Boston area, one of the largest centers of academic and biotech expertise in the U.S.”

The 13,000-square-foot facility serves as Ventus’ corporate offices and laboratories for its structural biology, biochemistry, protein sciences, molecular biology, and cellular biology teams focused on the identification and early characterization of small molecules using ReSOLVE, the company’s innovative, physics-based drug discovery platform. This new facility augments Ventus’ existing 10,000-square-foot facility in Montreal, which houses Ventus’ drug discovery and development organization, including its medicinal chemistry, computational chemistry, DMPK, and disease biology teams. The second phase of Ventus’ global expansion includes doubling the company’s footprint in Montreal with the planned opening of a new 23,000-square-foot facility in 2023 to further support the expansion of ReSOLVE and Ventus’ pipeline programs.

The ReSOLVE platform provides Ventus with a differentiated capability to analyze and see protein targets at a level of detail not available to others, leading to the identification of promising binding pockets that adopt many transient conformations. With these unique insights, Ventus can create dynamic blueprints, referred to as hydrocophores, that provide specific guidance on the size, shape, and polarity of each potential binding site and, using the hydrocophores, screen billions of compounds with great accuracy to generate novel chemical matter. As an end-to-end drug discovery platform, ReSOLVE allows Ventus to advance novel differentiated small molecules in a much more time- and cost-efficient manner than conventional drug discovery approaches.

About Ventus Therapeutics
Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation and neurology. The Company’s proprietary drug discovery platform ReSOLVE gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated small molecule medicines. The Company’s lead programs target key innate immune modulators, including NLRP3 and cGAS. The Company aims to use its ReSOLVE platform to improve the way medicines are discovered and developed, with the ultimate goal of restoring the health of people facing serious illnesses.  For more information, please visit www.ventustx.com and engage with Ventus on Twitter @Ventus_Tx or on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of the executive leadership team, Ventus’ business strategy, current programs, future results of operations, and financial position. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business and its efforts to address the impact on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers and manufacturers; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

Media Contact

Kyle Evans
ICR Westwicke